Drug profile · INN
levobupivacaine hydrochloride
CHIROCAINE
levobupivacaine hydrochloride (CHIROCAINE) is a sodium channel protein type iv alpha subunit blocker. Route of administration: injection. Current US regulatory status: approved.
Drug details — levobupivacaine hydrochloride
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
levobupivacaine hydrochloride (CHIROCAINE) is a sodium channel protein type iv alpha subunit blocker. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Sodium channel protein type IV alpha subunit blocker
Primary target: Sodium channel protein type 4 subunit alpha
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is levobupivacaine hydrochloride?
levobupivacaine hydrochloride (CHIROCAINE) is a sodium channel protein type iv alpha subunit blocker. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for levobupivacaine hydrochloride?
CHIROCAINE is a marketed brand name for levobupivacaine hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of levobupivacaine hydrochloride?
levobupivacaine hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.